Sustained Release Celecoxib From Bioerodible Intraocular Devices

Abstract

Purpose: : To determine the release properties of two different bioerodible Celecoxib devices, which could be potentially used to treat age-related macular degeneration, diabetc retinophathy and post cataract inflammation.

Methods: : Two types of sustained release devices were prepared. Device A was composed of a central core of Celecoxib in a bioerodible polermer matrix that was futher coated with a bioerodible poermer and heat cured. The devices were 0.9 mm in diameter and are disigned to be implantable. Device B was an in situ gelling system composed of Celecoxib and a bioerodible polymer in a biocompatible solvent (N-methyl-2-pyrrolidone). These systems are designed to be injectable through a 30 or 25 gauge needle. Release into phosphate buffer (pH 7.4) at 37^oC was measured over one month, buffer was regularly changed. Release rates were calculated from the culmulative release (determinbed by HPLC) versus time.

Results: : Release from Device A gave a fast release of 2µg/day for the first week, followed by a steady state release of approximately 1 µg/day. Device B provided a immediate release of 10µg, followed by a steady state release of approximately 2.5 µg/day.

Conclusions: : Both Device A and Device B provide long term constant release of Celecoxib. Initial data indicates a duration of over 6 months is possible. A key advantage of Device B may be its easiser administration (injectable via 30 gauge needle).

Keywords: diabetic retinopathy • cataract • age-related macular degeneration